Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Announces Commercial Expansion of the Cadence® Total Ankle System
PLAINSBORO, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced full commercial availability of its Cadence ® Total Ankle System, a new ankle prosthesis developed in partnership with four
View HTML
Toggle Summary Integra LifeSciences Introduces Next Generation CUSA® Clarity Ultrasonic Tissue Ablation System
PLAINSBORO, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a global leader in medical technology, announces the launch of its new CUSA® Clarity ultrasonic tissue ablation platform designed to deliver an innovative, integrated system for enhanced
View HTML
Toggle Summary Integra LifeSciences Launches Press-Fit Reverse Shoulder for Fracture for the Titan™ Modular Shoulder System
PLAINSBORO, N.J., March 15, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation   (Nasdaq:IART), a leading global medical technology company, announced the launch of the Titan™ Press-Fit Reverse Shoulder for Fracture. The use of the reverse shoulder to treat humeral fractures has
View HTML
Toggle Summary Integra LifeSciences to Present at the Barclays Global Healthcare Conference and Oppenheimer's 27th Annual Healthcare Conference in March 2017
PLAINSBORO, N.J., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it will present at the following conferences in March: At 9:00AM ET on Tuesday, March 14, 2017, Mr. Glenn Coleman, Chief Financial Officer and Corporate VP of
View HTML
Toggle Summary Integra LifeSciences Announces Acceptance of Shares Tendered into Offer for Derma Sciences, Inc.
PLAINSBORO, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ:IART), a global leader in medical technology, announced today that its tender offer by its wholly-owned subsidiary, Integra Derma, Inc. ("Offeror"), to purchase all outstanding common
View HTML
Toggle Summary Integra LifeSciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Updates 2017 Full-Year Guidance
2016 Results and 2017 Guidance in line with January 10, 2017 Preliminary Announcement
View HTML
Toggle Summary Integra LifeSciences Plans to Acquire the Codman Neurosurgery Business from Johnson & Johnson for $1.045 Billion in Cash
Enhances global position in neurosurgery by adding a complementary product portfolio and the world-recognized Codman brand Builds relevant scale, accelerates international growth and expands the neurosurgery sales channel Accelerates Integra's strategy to achieve aspirational targets of $2 billion
View HTML
Toggle Summary Integra LifeSciences to Host Its Fourth Quarter 2016 Earnings Results Conference Call on February 23, 2017
PLAINSBORO, N.J., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) will release its fourth quarter 2016 financial results on Thursday, February 23, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results.
View HTML
Toggle Summary Integra LifeSciences Commences Previously Announced Cash Tender Offer to Acquire Derma Sciences, Inc.
PLAINSBORO, N.J., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ:IART), a global leader in medical technology, announced today that its wholly-owned subsidiary, Integra Derma, Inc. ("Offeror"), is commencing a cash tender offer to purchase all
View HTML
Toggle Summary Integra LifeSciences to Acquire Derma Sciences Inc. and Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results and 2017 Outlook
Expands regenerative technology capabilities and accelerates advanced wound care strategy with the addition of amniotic tissue-based products Leverages existing sales channel with the addition of a complementary line of advanced wound care products Expects 7% to 8.5% organic revenue growth in 2017
View HTML